A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium - PubMed
4 hours ago
- #safety outcomes
- #immune checkpoint inhibitors
- #metastatic renal cell carcinoma
- Comparison of nivolumab plus cabozantinib (Nivo + Cabo) and pembrolizumab plus lenvatinib (Pem + Len) in metastatic renal cell carcinoma (mRCC).
- Study included 185 patients (81 Nivo + Cabo, 104 Pem + Len) from multiple institutions (2018-2025).
- Primary outcome: treatment-related adverse events (TrAEs); secondary: oncologic outcomes (ORR, PFS, CSS, OS).
- Any-grade TrAEs occurred in 90% (Nivo + Cabo) vs. 92% (Pem + Len), p=0.6.
- Severe TrAEs (grade ≥3) more frequent in Pem + Len (44%) vs. Nivo + Cabo (30%), p=0.048.
- No significant differences in ORR (66% vs. 71%, p=0.6), PFS, CSS, or OS in matched cohort.
- Conclusion: Similar oncologic efficacy, but Pem + Len associated with more severe TrAEs.
- Emphasizes careful toxicity management and shared decision-making for ICI-based combinations.